BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonan ...

April 12, 2011 — Phase 3 results with oral BG-12 (dimethyl fumarate; Biogen Idec) in relapsing-remitting multiple sclerosis (RRMS) show significant clinical responses and favorable safety and ...

Biogen Idec's oral BG-12 handily outstripped Teva's Copaxone in a Phase III study for multiple sclerosis, setting up a direct march to the FDA with positive late-stage data covering 2,600 patients.

WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced that U.S. and EU regulatory authorities have accepted the company's marketing applications for the review of BG-12 ...